| SGX Pharmaceuticals Submits Investigational New Drug Application For ...
SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for SGX523. This compound is an internally developed, orally-bioavailable, small molecule inhibitor of the cMET receptor tyrosine kinase. The Company expects to begin Phase I clinical trials of SGX523 for solid tumor cancer patients in early 2008.
"This IND submission is one quarter earlier than originally anticipated and represents a significant achievement for our organization," said Mike Grey, President and Chief Executive Officer of SGX Pharmaceuticals. "Submission of the SGX523 IND package less than ten months after the compound's nomination as a formal development candidate speaks highly of the effectiveness of our research and development capabilities.
Drug Slows Prostate Tumor Growth By Keeping Vitamin A Active
ScienceDaily (Nov. 8, 2007) A novel compound that blocks the breakdown of retinoic acid, derived from vitamin A, is a surprisingly effective and "promiscuous" agent in treating animal models of human prostate cancer, say investigators from the University of Maryland, Baltimore (UMB). .
The foggy world of chemobrain
Almost one-quarter of women diagnosed with breast cancer are under the age of 45. Many of these women find the information and programs available to them don't match the psychosocial and financial stress young women face following a breast cancer diagnosis. The National Conference for Young Women with Breast Cancer, being held this weekend at the Downtown Sheraton, addresses the issue and provides relevant information from sexuality, nutrition and exercise, to clinical trials and advocacy. http://www.cbcn.ca/ywbcc/ .
Scan can tell if body is cancer-free
A whole-body PET scan may be just what the doctor orders now to tell women how successful their cervical cancer treatment has been. Researchers at Washington University say they have found that a PET scan three months after treatment ends can determine whether a woman is disease-free -- or whether she needs additional therapy. "This is the first time we can say that we have a reliable test to follow cervical cancer patients after therapy," said Dr. Julie E. Schwarz, a resident in the Department of Radiation Oncology. "If the scan shows a complete response to treatment, we can say with confidence that they are going to do extremely well. That's really powerful." Without a test like PET (positron emission tomography), it can be difficult to tell whether treatment has destroyed the cervical tumors, Schwarz said.
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial ...
CHICAGO, Nov. 15 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (NASDAQ: ADLS) , today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States. The primary efficacy endpoint of statistical non-inferiority in the clinical cure rate at the test-of-cure visit was achieved. The study results showed that cethromycin cured 94.0% of patients with CAP, compared to Biaxin(R) (clarithromycin), a current standard of care treatment for CAP, which cured 93.8% of studied patients in the per protocol population. In the modified intent to treat population, cethromycin cured 83.1% of patients and Biaxin cured 81.1%.
Exercise, Psychological Counseling Could Ease Cancer-Related Fatigue
Cancer patients suffering from symptoms of fatigue might find some relief through regular exercise and psychological counseling to deal with stress, according to a new review.Fatigue is one of the most common symptoms of patients with cancer and those undergoing treatment with radiation and chemotherapy. According to the American Cancer Society, 90 percent of patients in cancer treatment experience fatigue that can range from �mild lethargy to feeling completely wiped out.�The reviewers, led by Paul Jacobsen of the H. Lee Moffitt Cancer Center in Tampa, Fla., said that fatigue affects patients� quality of life, with one-third feeling that it, �interferes with their ability to work, relationships with others and physical and emotional well-being.�There has been growing interest in helping these patients manage the symptoms of exhaustion with nonpharmacological treatments, and the systematic review aimed to determine the effectiveness of psychological therapy and exercise in meeting the goal.The review appears in the November issue of the journal Health Psychology.
Long-awaited blueprints to guide cancer survivors' future care
A new push is on to provide patients with "survivor plans," long-awaited blueprints for the customized follow-up care they'll require for years. Few today get that careful send-off as they leave cancer specialists and head back to their regular doctors, even though the Institute of Medicine alerted the nation two years ago that these survivors' special needs weren't being met. .
Prostate Cancer Radiotherapy Won't Affect Sexual Function
MONDAY, Oct. 29 (HealthDay News) High-dose precision radiation therapy doesn't harm the sexual function of prostate cancer patients, U.S. researchers say. A team at Fox Chase Cancer Center in Philadelphia tracked 155 men with intermediate- to high-risk prostate cancer who underwent intensity-modulated radiation therapy (IMRT), a technique that more precisely targets the tumor. "IMRT is revolutionizing how we treat men with prostate cancer, because it improves our ability to avoid normal tissue. As a result, more radiation dose can be delivered to the prostate by increasing the amount of radiation each day. Increasing the radiation used each day is particularly attractive, because it also shortens the treatment time by several days," study lead author Dr. Mark Buyyounouski, attending physician in the radiology department at Fox Chase, said in a prepared statement.
|
